Maze Therapeutics
- Founded: 2019
- Location: South SF, CA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: Pompe disease (partner: Sanofi)
- Drug types: RAR, GEN, MUS, NPH, CVV, NEU, OPH, GER
- Lead product: MZE001
- Product link: https://mazetx.com/pipeline/
- Funding: $190M Jan 2022; $191M Feb 2019
- Investors: Third Rock, Arch
mazetx.com linkedin.com job board
Short description:
Small Molecules, Gene Therapy, Antisense Oligonucleotides, Biologics
Drug notes:
Undisclosed programs RD/Clin0 kidney diseases, cardiovascular condition, ALS, glaucoma, AMD
Long description:
Maze therapeutics is translating genetic insights into new medicines. Advances in human genome sequencing and functional genomics now offer the chance to decode the mysteries of the genetics of disease. Maze is exploiting these advances to map novel connections between known genes and disease. Maze navigates genetic diversity with their proprietary Compass platform that combines human genetic data, functional genomics tools and data science technology. Maze is leveraging Compass for target identification, drug discovery and drug development to unlock the central tenet of precision medicine: to deliver the right drug, to the right patient, at the right time. Maze is currently pursuing programs in metabolic, cardiovascular and renal diseases.
© 2023 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com